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Abstract
Background: To identify different response patterns to intravitreal dexamethasone implants (IDI) in naïve and
previously treated (PT) diabetic macular edema (DME) eyes in a real-life setting.
Methods: 342 IDI injections (203 DME eyes) were included. Number of IDI injections, percentage (%) of eyes with 1,
2, 3 and ≥ 4 injections, time to reinjections, visual acuity (VA), intraocular pressure (IOP) and central retinal thickness
(CRT) were evaluated for naïve and PT DME eyes over 24 months.
Results: Mean number of injections was significantly lower in naïve vs PT DME eyes (1.40 ± 0.9 vs 1.82 ± 0.9,
p < 0.001). The percentage of eyes receiving 1 injection was significantly higher in naïve vs PT DME eyes
(76.1 vs 47.7), (p < 0.001). However, it was significantly lower for 2 (16.4 vs 29.4), or 3 injections (1.4 vs 17.6)
(both p < 0.001), with no differences in eyes receiving ≥4 injections (5.9 vs 5.1 respectively, p = 0.80). Mean
time to reinjection was not significantly different between both groups for the second, third and fourth
injection (9.6 ± 4.0 vs 10.0 ± 5.5, p = 0.75, 13.2 ± 4.0 vs 16.0 ± 3.5, p = 0.21 and 21.7 ± 3.8 vs 19.7 ± 5.8, p = 0.55).
VA scores were consistently better in naïve vs PT DME eyes at all studied timepoints, with no significant
differences in CRT reduction or adverse effect rates.
Conclusion: Naïve DME eyes received lower number of IDI injections and showed better VA levels than PT
DME eyes for 24 months in a real-world setting. This data supports the IDI use in early DME stages and
provide further evidence of better IDI response when used as first-line therapy.
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Summary statement
Intravitreal dexamethasone implants provide better re-
sponse in naïve than previously treated diabetic macular
edema eyes with better visual outcomes and lower num-
ber of injections over 24-months, in a large real-world
cohort of eyes treated in routine clinical care outside
clinical trial criteria.
Background
Diabetic macular edema (DME) is a complex disease of
multifactorial origin in which fluid accumulates in the
retinal layers due to the disruption of blood retinal bar-
rier and increased vascular permeability [1–3]. Treat-
ment options to manage DME include intravitreal
injections of anti-vascular endothelial growth factor
(anti-VEGF) or intravitreal corticosteroids (i.e. dexa-
methasone, fluocinolone acetonide and triamcinolone
acetonide) [4–6]. The intravitreal dexamethasone im-
plant (IDI, 0.7 mg, Ozurdex®: Allergan, Inc., CA, USA) is
a biodegradable, sustained-release drug delivery system
that releases dexamethasone into the vitreous for up to
6 months, and is currently approved for the treatment of
macular edema secondary to retinal vein occlusion [7],
non-infectious posterior uveitis [8] and DME, based on
the results of the MEAD trial [9]. This study pooled the
data from 2 randomized, multicenter, masked, sham-
controlled, phase 3 clinical trials (ClinicalTrials.gov iden-
tifiers NCT00168337 and NCT00168389), that demon-
strated visual and anatomic improvements in DME eyes,
which were confirmed in subsequent trials [10, 11].
However, significant concerns appear with regards to
the applicability of clinical trials results to real world
scenarios. First, in clinical practice, the selection criteria
are less strict, usually limited to failure of other therap-
ies. This fact is especially relevant as eyes treated with
IDIs in routine clinical practice are often those in which
other therapies have primarily failed (laser, anti-VEGFs,
etc.) and are at risk of developing chronic macular
edema, limiting their potential for greater visual gains.
Second, the visit and treatment schedule applied in clin-
ical trials rarely reflects real world clinical conditions. In
particular, in the MEAD trial reinjections of the IDI
could not be performed prior to 6-months, limiting the
potential of the implant to achieve greater visual gains in
poor responsive eyes. Third, the potential loss of follow-
up visits can produce an overestimation of the benefits
and/or an underestimation of its side effects, affecting ei-
ther way the outcomes reported in comparison to clin-
ical trials. For these different reasons, it is important to
evaluate the IDI performance in real-life scenarios.
Currently, anti-VEGF therapies are considered the
first-line therapy for DME, and meanwhile the import-
ance of corticosteroid therapy has been recognized it is
mainly employed as a second-line therapy. As suggested
by the EURETINA guidelines for the management of
DME [12], IDIs are only considered as first-line therapy
in patients whose medical history excludes the use of
anti-VEGF therapies or in specific conditions: history of
major cardiovascular events, unwillingness to receive
monthly injections, or pseudophakic patients. Neverthe-
less, there is a growing body of evidence in the last years
supporting the benefits of IDIs in naïve DME patients,
and several studies have reported better visual outcomes
compared to refractory DME eyes [13, 14]. In contrast,
very few studies have evaluated specifically the treatment
frequency and the number of injections in naïve DME
eyes compared to previously treated eyes.
Thus, the purpose of the present study is to audit
the use of the IDI in a large series of DME eyes
treated in real-life clinical conditions, to identify dif-
ferent treatment patterns in naïve versus previously
treated eyes. The study was performed over a 5-year
period at two tertiary referral retinal units from a
well-defined geographic area that covered a popula-
tion of 1.8 million individuals. In addition, a specific
sub-analysis was carried out to identify differences in
baseline characteristics, VA, anatomical outcomes,
number of injections and reinjection frequency in
naïve eyes (defined as eyes with no prior intravitreal
therapies) and previously treated eyes (which previ-
ously received intravitreal drugs). The results obtained
were compared to those reported in the literature in
clinical trials (e.g., MEAD, CHAMPLAIN, BEVOR-
DEX) and previous real world published studies, to
address the performance of IDI in a large cohort of
unselected DME eyes in real-life conditions.
Methods
Study design
This study was approved by the Institutional Review
Board (IRB) at the Hospital Clinic of Barcelona and it
was conducted in accordance with the Tenets set forth
in the Declaration of Helsinki (HCB/2016/0905). Clinical
data were collected retrospectively from 2 specialized
tertiary referral retina clinics in Barcelona (Spain): Insti-
tut Clínic de Oftalmología (ICOF) at Hospital Clinic of
Barcelona and Hospital Vall d’Hebrón. No written in-
formed consent was required as data was retrospectively
collected from routine clinical care, as approved by the
reference IRB. All eyes receiving IDI injections for DME
between October 2010 and May 2015 were included in
the study. A comprehensive dataset was distributed and
completed in both study centers within the predeter-
mined timeframe. Patient identifiers were removed to
anonymize the data, and data from the individual centres
were collated and merged into a centralized database for
analysis.
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Clinical data collection
Data collected included demographics (age, gender, etc.),
laterality, previous local treatments, number of previous
injections, number of injections, surgical details, compli-
cations, current topical treatments, visual acuity (VA),
intraocular pressure (IOP) and central retinal thickness
(CRT) assessed by optical coherence tomography (OCT).
This data was collected at all the study timepoints: base-
line, 1–2 weeks, 6–8 weeks, and 3, 6, 9, 12, 18 and 24-
months post-injection of the first IDI. Additional data
was collected at each individual repeated injection dur-
ing the study, including VA, IOP and CRT data prior to
the procedure, and 1–2 weeks, 6–8 weeks, and 3 and 6-
months post-procedure.
Data sources/outcome measurements
All original data were gathered in routine clinical care
visits. All injections data (i.e. injection date, number of
injections, pre and post-injection data) were collected as
described above. At each time point, VA was determined
as the best VA with habitual correction or pinhole, ra-
ther than as the best-corrected refracted VA and pre-
sented in logarithm of the mínimum angle of resolution
(logMAR) units. The analysis of eyes with a low VA was
undertaken by substituting counting fingers (CF) and
hand movement (HM) with 2.0 and 2.3 logMAR, re-
spectively [15]. IOP measurements were obtained by
Goldmann tonometry and presented in mmHg. The
CRT was determined by OCT imaging using one of 2
different devices depending on the participating center
(Hospital Clínic, Cirrus HD-OCT®, Dublin, CA, USA
and Hospital Vall de Hebrón, Spectralis OCT®, Heidel-
berg Engineering, Germany). No research softwares were
employed to control for inter-device measurement dif-
ferences in CRT. No missing value substitutions were
performed in patients where data were not available for
a particular visit or were lost during follow-up.
Statistical analysis
Descriptive, frequency statistics and the chi-squared test
were used to assess the qualitative variables. The
normality of quantitative variables was examined in his-
tograms, and inter-group differences where evaluated
with an independent Student’s T-test and Mann-
Whitney U-test, when appropriate. A paired t-test was
used to compare pre- and post-treatment changes. For
VA change analysis, VA values are converted and pre-
sented in ETDRS letters. The cumulative probability of
IOP events occurring after IDI injection are presented as
survival curves using the Kaplan Meier (KM) method
[16]. High IOP was defined as an IOP greater than 21
mmHg, 25 mmHg or 35mmHg, as described elsewhere
[17]. The probability of IOP elevation was evaluated for
naïve and previously treated DME eyes subgroups, and
KM survival curves were compared with the log-rank
test. A p-value ≤0.05 was considered significant.
Results
Baseline demographic and clinical characteristics of study
cohort
A total of 203 DME eyes from 179 patients treated with
IDIs were included in this study. The baseline character-
istics of the patients and study eyes are disclosed in
Table 1. In this cohort, 67 eyes (33%) were treatment-
naïve, whereas 136 eyes (67%) had previously received
intravitreal treatment for DME. Previous intravitreal
treatments included intravitreal triamcinolone (IVTA) in
27 eyes (13.3%), anti-VEGF drugs in 84 eyes (41.3%),
and both IVTA and anti-VEGF treatment in 25 eyes
(12.3%). Overall, previous laser treatment was performed
in 154 eyes (75.8%), distributed as macular focal/grid
laser therapy in 113 eyes (55.6%) and pan-retinal photo-
coagulation (PRP) in 110 eyes (54.1%). Mean baseline
VA of the overall cohort was 0.92 logMAR (equivalent
to 39 ETDRS letters) and mean CRT was 498.7 μm. A
detailed comparison between naive and previously
treated eyes at baseline is shown in Table 1.
Number of injections and treatment burden
In the overall cohort, a total of 342 IDI injections were
administered in 203 eyes, with a mean number of injec-
tions of 1.68 ± 0.9 implants in a mean follow-up time of
16.3 ± 7.7 months (Table 2). The percentage of study
eyes in the overall cohort receiving 1 injection was
57.1% (116 eyes), 2 injections was 25.1% (51 eyes), 3 in-
jections was 12.3% (25 eyes) and > =4 injections was
5.4% (11 eyes). In this cohort, the mean time to reinjec-
tion was 9.95 ± 5.2 months for the 2nd injection, 15.71 ±
4.8 months for the 3rd injection and 20.4 ± 5.1 months
for the 4th injection.
When comparing naïve vs previously treated eyes, the
mean number of injections was 1.4 ± 0.9 vs 1.82 ± 0.9
(p < 0.001) in a mean follow-up time of 14.5 ± 7.8 vs
17.1 ± 7.9 months (p = 0.02), respectively. The percentage
of eyes receiving 1 injection was significantly higher in
naïve vs previously treated eyes (76.1% vs 47.7%, p <
0.001), as was significantly lower in eyes requiring 2 in-
jections (16.4% vs 29.4%, p = 0.04) or 3 injections (1.4%
vs 17.6%, p = 0.001). No differences were observed in the
percentage of eyes requiring > = 4 injections (5.9% vs
5.1%, p = 0.80). Interestingly, no differences between
groups were observed in the time to reinjection for 2nd
injection (9.61 ± 4.0 vs 10.0 ± 5.5 months, p = 0.75), 3rd
injection (13.2 ± 4.0 vs 16.0 ± 3.5 months, p = 0.21) and
4th injection (21.75 ± 3.8 vs 19.75 ± 5.8 months, p =
0.55). All these results are presented in Table 2.
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Visual acuity outcomes
The distribution of eyes by VA levels at each individual
timepoints is presented in Fig. 1. In the overall cohort, at
baseline the percentage of eyes with VA < 0.4 logMAR
was 6%, VA ≥0.4–0.7 was 24%, VA ≥0.7–1.0 was 42.5%
and VA > 1.0 was 27.5%. At 24 months, the percentage
of eyes with VA < 0.4 logMAR was 18.5%, VA ≥0.4–0.7
was 25.7%, VA ≥0.7–1.0 was 28.5% and VA > 1.0 was
27.1%. The percentage of eyes with good VA levels
(< 0.4 logMAR and ≥ 0.4–0.7 logMAR) was significantly
higher in naïve vs previously treated eyes in all study time-
points (all p < 0.05), as presented in Fig. 1.
In the overall cohort, mean baseline VA was 0.92 ±
0.4 LogMAR, at 6–8 weeks was 0.76 ± 0.4 LogMAR
and at 24 months was 0.8 ± 0.5 LogMAR (Fig. 2 and
Table 3). At 24 months, mean VA improvement was
+ 6 letters at 24 months in the overall cohort, with no
significant differences in subgroup analysis in
Table 1 Patient demographics and clinical characteristics of the study eyes at baseline
Characteristic Total (N = 203) Treatment-naïve eyes (N = 67) Previously treated eyes (N = 136)
Age mean years ± SD (range) 66.8 ± 10.3 (43–99) 66 ± 12.9 (43–99) 67 ± 8.9 (44–86)
Gender, n (%)
Female 87 (42.9) 27 (40.3) 61 (44.9)
Male 116 (57.1) 40 (59.7) 75 (55.1)
Lens status in study eye, n (%)
Phakic 105 (51.7%) 41 (61.2) 64 (47)
Pseudophakic 98 (48.3%) 26 (38.8) 72 (53)
Previous intravitreal therapy, n (%)
IVTA 27 (13.3) 0 (0) 27 (19.8)
Anti VEGF 84 (41.3) 0 (0) 84 (61.7)
IVTA + Anti VEGF 25 (12.3) 0 (0) 25 (18.3)
Previous laser therapy, n (%)
Any 154 (75.8) 38 (56.7) 116 (85.2)
Focal/grid 113 (55.6) 25 (37.3) 88 (64.7)
PRP 110 (54.1) 28 (41.7) 82 (60.2)
Mean VA, ETDRS letters (Snellen equivalent) a 39 (20/160) 42.5 (20/160) 37.5 (20/200)
Mean CRT, μm (SD) 498.7 ± 136 482.1 ± 127.5 506.5 ± 139.7
IVTA Intravitreal triamcinolone acetonide, VEGF Vascular endothelial growth factor, PRP Pan-retinal photocoagulation, VA Visual acuity; aLogarithm of the minimum
angle of resolution values are converted into ETDRS letters, CRT Central retinal thickness
Table 2 Number of Injections and time to reinjection during the study period
Total (N = 203) Naïve (N = 67) Previously treated (N = 136) P value
Total number of Injections, N (%) 342 (100%) 94 (27.4%) 248 (72.6%)
Number of Injections, Mean ± SD (Median-IQR) 1.68 ± 0.9 (1–1) 1.40 ± 0.9 (1–0) 1.82 ± 0.9 (2–1) < 0.001
Follow up time (months), Mean ± SD (Median-IQR) 16.3 ± 7.7 (16.1–13.8) 14.5 ± 7.8 (12.4–13.7) 17.1 ± 7.6 (17.4–13.1) 0.02
Number of injections, n (% study eyes)
1 injection 116 (57.1%) 51 (76.1%) 65 (47.7%) < 0.001
2 injections 51 (25.1%) 11 (16.4%) 40 (29.4%) 0.04
3 injections 25 (12.3%) 1 (1.4%) 24 (17.6%) < 0.001
≥ 4 injections 11 (5.4%) 4 (5.9%) 7 (5.1%) 0.80
Time to reinjection after 1st injection (months), Mean ± SD (Median-IQR)
2nd injection 9.95 ± 5.2 (8–5) 9.61 ± 4.0 (8–3.75) 10.0 ± 5.5 (8–5) 0.75
3rd injection 15.71 ± 4.8 (15–7.5) 13.2 ± 4.0 (11–3) 16.0 ± 3.5 (16–7) 0.21
4th injection 20.4 ± 5.1 (19.5–8) 21.75 ± 3.8 (21.5–5.75) 19.75 ± 5.8 (18–5.25) 0.55
SD Standard deviation, IQR Interquartile range
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treatment-naïve and previously treated eyes (+ 4.5 let-
ters vs + 6.5 letters, p = 0.70, Table 3). However,
treatment-naïve eyes maintained better mean VA at
all timepoints compared to previously treated eyes,
with significant differences at 6–8 weeks (mean VA
0.65 ± 0.47 vs. 0.81 ± 0,47, p < 0.05) and 3 months
(mean VA 0.68 ± 0,53 vs. 0.83 ± 0.46, p < 0.05)
(Fig. 2).
Fig. 1 Distribution of diabetic macular edema (DME) study eyes by visual acuity level at all timepoints. a. Overall cohort. b: Naïve eyes. c:
Previously treated eyes. At baseline, eyes with very good vision (black) and very poor vision (dark gray) were treated with the implant in routine
clinical care. These two categories fall outside the MEAD clinical trial inclusion criteria and represent 33.5% of the study cohort (6 and 27.5%,
respectively), highlighting the need for real world studies to evaluate the performance of the implant outside clinical trial scenarios. Naïve DME
eyes showed consistently greater percentages of eyes with good vision (black and light gray) than previously treated DME eyes at all timepoints
over 24 months. (Visual acuity levels; black: < 0.4 logMAR; light gray: ≥0.4–0.7 logMAR; medium gray: ≥0.7–1.0 logMAR; dark gray: > 1.0 logMAR)
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Central retinal thickness outcomes
The evolution of CRT changes from baseline in the overall,
naïve and previously treated eyes cohorts is presented in Fig. 3
and Table 3. Significant improvements were observed in CRT
at 6–8 weeks (− 181.8 μm, p < 0.05) and at 24 months
(− 96.1 μm, p < 0.05). In the subgroup analysis, no differ-
ences were observed in CRT improvements between naïve
and previously treated eyes at 6–8weeks (− 179.7 μm vs −
182.8 μm) or 24months (− 141.5 μm vs − 79.0 μm, p = 0.46).
Intraocular pressure outcomes
All IOP outcome measures are presented in Fig. 4.
The cumulative probability of IOP ≥ 21 / 25 / 35
mmHg at 12 months was 50% / 23% / 6%, and at 24
months was 60% / 30% / 7%, respectively. No signifi-
cant differences in IOP elevations were observed be-
tween naïve and previously treated eyes. At baseline,
41 eyes (20.2%) were already on treatment with top-
ical IOP-lowering drugs. The cumulative probability
of requiring IOP-lowering drops was 21.8% at 12
months and 46.2% at 24 months in the overall cohort,
with no significant differences between naïve and pre-
viously treated eyes. Glaucoma surgery was only re-
quired in 1 case (0.49%), that had pre-existing
glaucoma and was already on IOP lowering medica-
tions prior to first injection. The effect of repeat IDI
injections on IOP was also evaluated, and no signifi-
cant differences were observed in the cumulative
Fig. 2 Visual acuity outcomes. Evolution of mean visual acuity from baseline to 24 months in the overall cohort (solid line), naïve eyes (stripped
line) and previously treated eyes (dotted line). Significant differences were observed between naïve and previously treated eyes at 6–8 weeks and
3months timepoints (*p < 0.05)
Table 3 Outcome measures before and 24months after treatment in naïve vs previously treated eyes
Total (N = 203) Naïve (N = 67) Previously treated (N = 136) p-value
Mean VA, ETDRS letters
Before treatment (mean ± SD) (Snellen equivalent) 39 ± 61 (20/160) 42.5 ± 57.5 (20/160) 37.5 ± 62.5 (20/200) 0.19
After treatment (mean ± SD) 45 ± 57.5 (20/125) 47 ± 60 (20/125) 44 ± 56 (20/125) 0.71
Mean Change 6 4.5 6.5 0.70
Mean CRT, μm
Before treatment (mean ± SD) 498.7 ± 136 482.1 ± 127.5 506.5 ± 139.7 0.25
After treatment (mean ± SD) 402.6 ± 154.83 340.5 ± 88.28 427.4 ± 165 0.10
Mean Change −96.1 −141.5 −79.0 0.46
VA Visual acuity, ETDRS Early treatment diabetic retinopathy study, CRT Central retinal thickness, SD Standard deviation, IQR Interquartile range
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probability of any IOP level 6 months after the first,
second or third injection.
Discussion
This study reports better visual outcomes and reduced
treatment burden in naïve DME eyes compared to previ-
ously treated DME eyes, based on a large cohort of
DME patients treated with the IDI in routine clinical
care. The results of this study support the use of the IDI
in early DME stages in patients who do not qualify for
anti-VEGF therapy and provide further evidence of bet-
ter IDI response when used as first-line therapy com-
pared to its use as second-line therapy, after previous
failed intravitreal treatments.
Our real-world cohort of DME patients presented dif-
ferent demographics and baseline clinical characteristics
from those reported in clinical trials, overall with a
worse mean baseline VA [9, 10, 13, 18, 19] and CRT [9,
10, 18, 19]. In our series, a significant number of study
eyes were treated in routine clinical care with VA levels
that fall outside the inclusion criteria used in the MEAD
trial (33.5% of the study cohort, 6% with VA better than
0.4 logMAR and 27.5% with VA worse than 1.0 logMAR,
as presented in Fig. 1). This data is of particular rele-
vance, as reflects more closely the situation in which
such a therapy is to be employed in routine clinical care:
patients that require a therapeutic option even though
they might not conform to the ideal profile, either in
terms of specific disease related parameters, prior treat-
ment failure or co-morbidities. In case of our cohort of
previously treated eyes, their basal clinical characteristics
are generally worse than those reported previously in
real-world studies, particularly with lower baseline VA
[13, 14, 20–24] and greater CRT [20, 25]. Moreover,
more eyes had received prior treatment, particularly with
anti-VEGF and/or IVTA, than the study cohorts in these
previous series [14, 20, 22, 24–26].
The overall results presented here are somehow com-
parable with those from previous smaller cohorts. In-
deed, previous assessments of the effect of IDI on
refractory and treatment-naive patients showed similar
decreases in CRT and improvement in VA in both re-
fractory and treatment-naive groups. Other real-life
studies have also shown similar improvements in VA
and CRT without serious adverse events, mainly in
smaller series over shorter follow-up periods [27–32]. In
our population of DME patients, IDI considerably im-
proved the VA relative to baseline in both treatment-
naive and previously treated patients, suggesting that IDI
therapy offers benefits to both types of patient. Never-
theless, naive eyes maintained a better mean VA than
previously treated eyes at all time points studied. A par-
ticularly significant improvement was observed in naïve
patients during the first 3 months relative to previously
treated eyes, suggesting they respond better in terms of
VA, consistent with earlier data [13, 14]. Moreover, in
our series the percentage of eyes with good VA levels
was consistently higher in naïve eyes vs previously
treated eyes at all study timepoints, as graphically pre-
sented in Fig. 1. Regarding anatomical changes, IDI
treatment improves the CRT at all time points during
the follow-up, both in treatment-naïve and previously
Fig. 3 Anatomical outcomes. Evolution of mean central retinal thickness change from baseline to 24 months in the overall cohort (solid line),
naïve eyes (stripped line) and previously treated eyes (dotted line). No significant differences were observed between naïve and previously
treated eyes at any timepoint
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treated eyes, with no significant differences between
these subgroups. This discrepancy between functional
and anatomical outcomes in DME has extensively been
reported in previous studies, that suggest that retinal
thinning may also be related with outer retinal layers at-
rophy preventing visual improvement, more common in
chronic DME eyes [33].
The need for frequent injections in DME represents a
considerable burden for patients, especially with anti-
VEGF drugs [34–36]. In different studies, fewer IDI in-
jections have been shown to be necessary to achieve
similar visual and anatomical outcomes in DME patients
[10, 11, 37], although the loss of vision mainly due to
cataract must be controlled, which may be more com-
mon when IDIs are used. Further head-to-head trials will
be needed to compare the efficacy of IDI and anti-VEGF
therapy based on the patients’ clinical characteristics at
baseline and their prior treatments, tailoring the treat-
ment choice individually in a case-by-case basis. To-
wards this personalized medicine approach, several
attempts have been recently reported to shed some light
on predictive biomarkers for IDI response, based in ret-
inal imaging (i.e. OCT) or aqueous samples [38–41].
Likewise, recent studies have been directed to identify
those patients who don’t respond to anti-VEGF
treatment, [42] as well as to determine the synergistic
and beneficial effect of IDIs in combination with other
treatments [43, 44].
Significantly fewer IDIs were administered to
treatment-naïve eyes than to previously treated eyes and
indeed, many more treatment-naïve eyes received just 1
injection than previously treated eyes. However, when
additional implants were required, the time to reinjec-
tion did not differ significantly between the two groups.
This is an important point, as suggest that reinjections
were timely performed in both groups when required.
Such differences have not always been detected when
this parameter has been compared between naïve and
non-naïve eyes [14, 20]. Our results raise the interesting
hypothesis that early treatment may reduce the
Fig. 4 Intraocular pressure outcomes. Cumulative probability of different levels of intraocular pressure (IOP) elevations (top-left: > 21 mmHg, top-
right: ≥25mmHg, bottom-left: ≥35mmHg) and IOP lowering treatment requirement (bottom-right). No significant differences were observed
between naïve and previously treated eyes for any item at any timepoint
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treatment burden associated to IDI therapy in naïve
DME, beyond the benefit already reported for refractory
DME eyes when used as second line therapy. It is well
recognized that managing DME with IDIs is generally
associated with a need for fewer injections than anti-
VEGF therapies, as well as longer periods between the
need for treatment. The benefits to be gained from this
need for fewer injections have already been recognised
in the EURETINA guidelines for DME, whereby IDI use
is recommended as a first-line therapy only in specific
subgroups of patients. If confirmed in future studies, this
finding may offer an additional reason to support the
use of IDI as first-line therapy in a wider spectrum of
DME eyes.
As found elsewhere, IDI therapy was well tolerated by
DME patients. The main adverse event was high IOP
but that could typically be managed with medication. In-
deed, while nearly a third of patients developed a high
IOP, it was controlled with topical antihypertensive
drugs. There is no evidence of a previously cumulative
effect of multiple injections on increased IOP, irrespect-
ive of pre-existing glaucoma or ocular hypertension
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Totan et al., 2016
[22]
DME-Treated 6 30 57* 517 56.7% 100% – 64* 411
Bansal et al., 2016
[23]
DME 14.53 52 44* 514.2 100% 67.2% – 51* 419.9
(6
months)
Bonnin et al., 2015
[24]
DME 4 39 51.5* 559 44% 49% 36% 81.5* 477




6 78 53.9 537.6 42.3% 52.6% 17.9% 60.1 384.6
CHROME












36 128 50.5 450 16.4% 70.3% 15.6% 60.6 280
IRGREL-DEX Iglicki
et al., 2019 [14]
DME naive
and treated
24 130 55* 575 15% 7.4% – 65.5* 294.4**
This study:
Zarranz-Ventura
et al. 2020 [6]
DME-All 24 203 39 498.7 75.8% 53.6% 25.6% 45 402.6
Naive 24 67 42.5 482.1 56.7% 0% 0% 47 340.5
Previously
treated
24 136 37.5 506.5*** 85.2% 80.1% 38.2% 44 427.4***
DME Diabetic macular edema, VA Visual acuity, CRT Central retinal thickness, VEGF Vascular endothelial growth factor, IVTA Intravitreal triamcinolone acetonide.
*Logarithm of the minimum angle of resolution values converted into ETDRS letters.** Calculated from publication data. *** CRT measurements obtained with 2
different OCT machines, unadjusted for inter-device differences
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(OHT) [17, 45]. However, the probability of taking IOP-
lowering medication increased considerably from 12
months to 24months, an important consideration when
using the IDI in routine clinical care [46].
Our study has some limitations, such as the retro-
spective design of the study. In addition, a detailed
comparison of the data obtained with that from previ-
ous clinical trials and other retrospective studies is
complicated by the fact that they involve cohorts with
different characteristics at baseline (Table 4). This is
particularly the case of DME severity and the inclu-
sion/exclusion criteria, and notably in terms of the
baseline VA that differs substantially between trials,
as well as the type and length of the prior treatments,
and the intervals between the repeated IDI injections.
Despite the absence of detailed comparisons, the re-
sults of the present study in a clinical setting are
somehow comparable to the data from clinical trials.
Furthermore, as the data is obtained from a cohort of
patients not included in a clinical trial it better re-
flects patients seen in clinical practice, both
treatment-naive and previously treated patients with
DME. Therefore, similar outcomes can be expected of
IDI treatment at other clinical centres for DME pa-
tients, as reported by previous smaller cohorts. More-
over, it is likely that the patients included in this
study are patients that might otherwise not be recom-
mended for such therapy as they do not conform to
the criteria employed in clinical trials. It should also
be noted that some of the patients considered to be
naïve to treatment in this study had received prior
laser therapy but not any prior intravitreal therapy.
This may contribute to explain differences in treat-
ment response and disease progression (and/or ad-
verse events) between this cohort of naïve patients
and those studied elsewhere. Finally, two different
OCT machines from two different manufacturers
were employed in this study (one in each participat-
ing center), but CRT measurements were not adjusted
for inter-device differences and this data should be
interpreted with caution, especially when comparing
these results with other clinical practice studies and
trial outcomes.
Conclusions
In summary, IDI treatment for DME in our cohort
produced favourable outcomes in both naïve and pre-
viously treated eyes. These results support the use of
IDIs to treat patients with DME in everyday clinical
practice, in patients that don’t conform to the strict
criteria employed in clinical trials. In addition, the
data presented here highlight the need for prospective
studies to assess the additional benefits of using IDI
over anti-VEGF therapies, and in particular, of the
use of such implants in naïve DME patients should
this additional effect in reducing the treatment bur-
den when compared to refractory DME patients is
confirmed in future studies. Such studies may lead to
the extension of the EURETINA guidelines that cur-
rently limit the recommendation of IDI as a first-line
therapy to only a few specific circumstances to a
wider spectrum of DME eyes.
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